Status:
COMPLETED
Observational Study on Multiple Sclerosis
Lead Sponsor:
Fondazione Italiana Sclerosi Multipla
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-55 years
Brief Summary
This is a multicentre observational study which involves 43 of the major Italian centres that treat MS. The duration expected for the study participation of each subject was exclusively the necessary ...
Eligibility Criteria
Inclusion
- Group A (MS)
- Age 18-55 years;
- Unisex patients diagnosed with MS according to McDonald criteria and successive relapse (38, 39), and subjects with CIS;
- Course of the disease: RR-SP-PP-CIS;
- Disease duration (starting from diagnosis): from 1 month to 25 years for subjects with RR, SP, and PP; a maximum of 5 years for subjects with CIS;
- Not in clinical relapse (at least 30 days after the last clinical relapse);
- Subjects treated or non-treated with immunomodulatory and immunosuppressive drugs;
- Signature of the informed consent.
- Group B (HC)
- Age 18-55 years;
- Absence of significant diseases and lack of familiarity with MS, ie health check-ups (HC);
- Signature of the informed consent.
- The subjects included in this group could be, for example, unrelated relatives or spouses of those affected by MS or other diseases in the study or linked to these by affinity restrictions (such as, the father-in-law with the son-in-law, the husband with his wife's brother, etc.) or accompanying persons or operators of other centres.
- Group C (OND)
- Aged 18-55 years;
- Subjects with other non-inflammatory neurodegenerative disease (OND), for example Parkinson, ALS, ataxy.
- Group D (ONDi)
- Age 18-55 years;
- subjects suffering of other inflammatory neurodegenerative diseases (ONDi), for example optical neuromielitys, ADEM, encephalitis, neuro lupus, neurological complications of systemic autoimmune diseases;
- Signature of the informed consent.
Exclusion
- • The presence of acute or chronic disease which are disabling or interfere with the design and objective of the study;
- Clinically proven cardiopathy (NYHA ≥ I class);
- Previous episodes of venal thromboembolism (including either deep venal thrombosis or pulmonary embolism);
- Neoplasms;
- Thrombophilia from an anamnestic definition;
- Diabetes;
- Primary or secondary pulmonary hypertension and in treatment for it;
- Concurrent systemic steroid treatments or in the last 30 days;
- Cerebrovascular diseases current or previous;
- Episodes of global transitory amnesia;
- Pregnancy.
Key Trial Info
Start Date :
December 29 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 30 2012
Estimated Enrollment :
1767 Patients enrolled
Trial Details
Trial ID
NCT04133779
Start Date
December 29 2010
End Date
May 30 2012
Last Update
October 21 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.